English  |  正體中文  |  简体中文  |  2823024  
???header.visitor??? :  30242644    ???header.onlineuser??? :  707
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"andrew d"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-3 of 3  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
國立成功大學 2019-08-6 Functional Relevance of Interleukin-1 Receptor Inter-domain Flexibility for Cytokine Binding and Signaling Ge;Jiwan;Remesh;Soumya, G.;Hammel;Michal;Pan;Si;Mahan;Andrew, D.;Wang;Shuying;Wang;Xinquan
國家衛生研究院 2017-06-26 Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S
國家衛生研究院 2016-06 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study Andrew, D;Ramesh, R;Brooke, B;Bruce, B;Deyaa, A;Eliel, B;Chen, LT

Showing items 1-3 of 3  (1 Page(s) Totally)
1 
View [10|25|50] records per page